Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Biodel's two ongoing pivotal phase III trials of VIAject to include European sites

Sep. 27, 2007

Positive results for DOV Pharmaceutical's phase Ib trial of DOV-21947

Sep. 27, 2007

Studies reveal increased bone formation with anti-sclerostin antibody

Sep. 27, 2007

Zelos reports positive results of phase I and II trials of Ostabolin-C

Sep. 27, 2007

Novel treatment option for obesity and related disorders reported in recent Glenmark patent

Sep. 26, 2007

Metabolex initiates phase II trial of MBX-8025 alone and with Lipitor

Sep. 26, 2007

Eucreas recommended for E.U. approval in type 2 diabetes

Sep. 26, 2007

Preclinical models, phase I study detail activity of ACE-011

Sep. 26, 2007

Odanacatib increases bone mineral density in postmenopausal women

Sep. 26, 2007

Pan-PPAR agonist PPM-204 lowers glucose and insulin in patients with type 2 diabetes

Sep. 26, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...